KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Restructuring Costs (2022 - 2025)

Historic Restructuring Costs for Pacira BioSciences (PCRX) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • Pacira BioSciences' Restructuring Costs rose 48454.13% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 120701.63%. This contributed to the annual value of $7.7 million for FY2024, which is 228806.82% up from last year.
  • Latest data reveals that Pacira BioSciences reported Restructuring Costs of $6.8 million as of Q3 2025, which was up 48454.13% from $634000.0 recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Restructuring Costs peaked at $10.9 million during Q4 2022, and registered a low of -$1.8 million during Q3 2024.
  • Moreover, its 4-year median value for Restructuring Costs was $1.9 million (2024), whereas its average is $2.9 million.
  • Per our database at Business Quant, Pacira BioSciences' Restructuring Costs plummeted by 98300.0% in 2024 and then surged by 48454.13% in 2025.
  • Pacira BioSciences' Restructuring Costs (Quarter) stood at $10.9 million in 2022, then tumbled by 113.4% to -$1.5 million in 2023, then soared by 430.6% to $4.8 million in 2024, then surged by 40.6% to $6.8 million in 2025.
  • Its Restructuring Costs was $6.8 million in Q3 2025, compared to $634000.0 in Q2 2025 and $6.2 million in Q1 2025.